🟢 Aquestive Therapeutics is trading 9.14% up in pre-market after positive Anaphylm usability and pharmacokinetic results

Aquestive Therapeutics is trading at $4.30 (+9.14%) after announcing positive topline human-factors and pharmacokinetic study results for Anaphylm.

• The data addresses FDA usability concerns involving packaging, film placement, and administration.
• Management plans to resubmit Anaphylm’s NDA in the third quarter of 2026, supporting renewed regulatory optimism.
• The move is company-specific while broader U.S. index futures remain mixed; second-quarter results are scheduled for August 11, 2026.